At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed May 28, 2026 at 09:04 ET
MiNK Therapeutics announced first patient dosing in a randomized Phase 2 trial (C-1300-02) evaluating agenT-797 for severe acute lung injury/ARDS. This is a clinical milestone with no revenue or earnings data, and preliminary efficacy readout is not expected until 2H 2026, making the near-term stock impact limited.
- First patient dosed in randomized Phase 2 trial (C-1300-02) for agenT-797 in severe acute lung injury/ARDS patients
- Trial compares agenT-797 + standard of care vs placebo + standard of care; primary endpoints include survival, ventilator-free days, and ICU recovery
- Dosing occurred at First Lviv Territorial Medical Union in Ukraine, with U.S. site expansion underway
- Preliminary data expected in second half of 2026, no near-term catalyst
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access